Influence of regular physical activity on warfarin dose and risk of hemorrhagic complications.

Impact of regular physical activity on weekly warfarin dose requirement. J Thromb Thrombolysis (2016) 0.75

Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med (2006) 32.81

Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. Lancet (2012) 20.56

Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Med Sci Sports Exerc (2007) 20.11

Gait speed and survival in older adults. JAMA (2011) 15.01

Global physical activity levels: surveillance progress, pitfalls, and prospects. Lancet (2012) 12.05

A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest (2010) 10.29

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med (2005) 8.77

Physical activity and public health in older adults: recommendation from the American College of Sports Medicine and the American Heart Association. Med Sci Sports Exerc (2007) 8.67

A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost (1993) 7.92

Interactive effects of fitness and statin treatment on mortality risk in veterans with dyslipidaemia: a cohort study. Lancet (2012) 6.29

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA (2002) 5.26

CYP4F2 genetic variant alters required warfarin dose. Blood (2008) 4.23

Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group. Ann Intern Med (1993) 4.03

Dose response between physical activity and risk of coronary heart disease: a meta-analysis. Circulation (2011) 3.84

Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J (2005) 3.75

Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med (1998) 3.44

Association of warfarin dose with genes involved in its action and metabolism. Hum Genet (2006) 3.27

Aging biology and geriatric clinical pharmacology. Pharmacol Rev (2004) 3.23

Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol (1998) 3.17

Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther (2006) 3.06

The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics (1996) 3.02

The largest prospective warfarin-treated cohort supports genetic forecasting. Blood (2008) 2.79

Physical activity and hemostatic and inflammatory variables in elderly men. Circulation (2002) 2.75

Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics (2006) 2.66

Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics (1994) 2.55

Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther (2007) 2.54

Guide to the assessment of physical activity: Clinical and research applications: a scientific statement from the American Heart Association. Circulation (2013) 2.37

Physical inactivity and idiopathic pulmonary embolism in women: prospective study. BMJ (2011) 2.34

Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. Pharmacogenomics (2008) 1.89

VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. Pharmacogenomics (2008) 1.65

Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol (2001) 1.59

Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev (2009) 1.56

VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb Haemost (2005) 1.55

Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics (2001) 1.53

Habitual physical activity is associated with endothelial function and endothelial progenitor cells in patients with stable coronary artery disease. Eur J Cardiovasc Prev Rehabil (2009) 1.51

Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy. Thromb Haemost (2011) 1.35

Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics. Annu Rev Pharmacol Toxicol (2005) 1.31

Influence of CYP2C9 Genotype on warfarin dose among African American and European Americans. Per Med (2007) 1.26

Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients. J Hum Genet (2006) 1.21

Warfarin dosing and cytochrome P450 2C9 polymorphisms. Thromb Haemost (2004) 1.12

Racial differences in the prevalence of Factor V Leiden mutation among patients on chronic warfarin therapy. Blood Cells Mol Dis (2006) 1.00

Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation. Circ Arrhythm Electrophysiol (2012) 0.97

Effect of exercise training on vascular endothelial function in patients with stable coronary artery disease: a randomized controlled trial. Eur J Prev Cardiol (2011) 0.97

Influence of physical activity on warfarin therapy. Thromb Haemost (1998) 0.90

Public health: Health risks of physical inactivity similar to smoking. Nat Rev Cardiol (2012) 0.88

The effects of high physical activity on pharmacokinetic drug interactions. Expert Opin Drug Metab Toxicol (2011) 0.83

Role of exercise and physical activity on haemophilic arthropathy, fall prevention and osteoporosis. Haemophilia (2011) 0.83

Physical activity reduces salt sensitivity of blood pressure: the Genetic Epidemiology Network of Salt Sensitivity Study. Am J Epidemiol (2012) 0.80

Physical activity and risk of cerebrovascular disease in the European Prospective Investigation into Cancer and Nutrition-Spain study. Stroke (2012) 0.79

Endothelial function and endothelial progenitors: possible mediators of the benefits from physical exercise? Eur J Cardiovasc Prev Rehabil (2009) 0.76

Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation (2010) 30.07

Heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation (2009) 27.89

Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation (2014) 22.74

Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic Impact Goal through 2020 and beyond. Circulation (2010) 13.28

Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation (2015) 10.14

Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke (2011) 10.11

Executive summary: heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation (2010) 9.18

Mixed linear model approach adapted for genome-wide association studies. Nat Genet (2010) 8.47

Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation (2009) 8.11

A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med (2013) 7.09

Overweight in children and adolescents: pathophysiology, consequences, prevention, and treatment. Circulation (2005) 7.04

A genome-wide association study for blood lipid phenotypes in the Framingham Heart Study. BMC Med Genet (2007) 5.64

The relationship between visit-to-visit variability in systolic blood pressure and all-cause mortality in the general population: findings from NHANES III, 1988 to 1994. Hypertension (2011) 5.14

Common missense variant in the glucokinase regulatory protein gene is associated with increased plasma triglyceride and C-reactive protein but lower fasting glucose concentrations. Diabetes (2008) 4.20

Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet (2013) 3.21

Association of race and sex with risk of incident acute coronary heart disease events. JAMA (2012) 3.07

Traditional cardiovascular risk factors in relation to left ventricular mass, volume, and systolic function by cardiac magnetic resonance imaging: the Multiethnic Study of Atherosclerosis. J Am Coll Cardiol (2006) 2.94

Executive Summary: Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation (2016) 2.87

Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study. Arterioscler Thromb Vasc Biol (2007) 2.54

Chocolate consumption is inversely associated with prevalent coronary heart disease: the National Heart, Lung, and Blood Institute Family Heart Study. Clin Nutr (2010) 2.40

Differences in left ventricular structure between black and white hypertensive adults: the Hypertension Genetic Epidemiology Network study. Hypertension (2004) 2.36

Genetic loci associated with plasma phospholipid n-3 fatty acids: a meta-analysis of genome-wide association studies from the CHARGE Consortium. PLoS Genet (2011) 2.33

Genetic ancestry is associated with subclinical cardiovascular disease in African-Americans and Hispanics from the multi-ethnic study of atherosclerosis. Circ Cardiovasc Genet (2009) 2.31

Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol (2009) 2.13

Trends in blood pressure, hypertension control, and stroke mortality: the Minnesota Heart Survey. Am J Med (2006) 2.10

Genetic variants associated with cardiac structure and function: a meta-analysis and replication of genome-wide association data. JAMA (2009) 2.10

The -256T>C polymorphism in the apolipoprotein A-II gene promoter is associated with body mass index and food intake in the genetics of lipid lowering drugs and diet network study. Clin Chem (2007) 2.03

Dietary linolenic acid is inversely associated with calcified atherosclerotic plaque in the coronary arteries: the National Heart, Lung, and Blood Institute Family Heart Study. Circulation (2005) 2.03

Hypertension and smoking are associated with reduced regional left ventricular function in asymptomatic: individuals the Multi-Ethnic Study of Atherosclerosis. J Am Coll Cardiol (2006) 1.98

Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. Pharmacogenomics (2008) 1.89

A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry. Nat Genet (2013) 1.82

Stroke Genetics Network (SiGN) study: design and rationale for a genome-wide association study of ischemic stroke subtypes. Stroke (2013) 1.80

Genome-wide meta-analysis points to CTC1 and ZNF676 as genes regulating telomere homeostasis in humans. Hum Mol Genet (2012) 1.77

Apolipoprotein E polymorphisms and postprandial triglyceridemia before and after fenofibrate treatment in the Genetics of Lipid Lowering and Diet Network (GOLDN) Study. Circ Cardiovasc Genet (2010) 1.77

Comparison of the Framingham Heart Study hypertension model with blood pressure alone in the prediction of risk of hypertension: the Multi-Ethnic Study of Atherosclerosis. Hypertension (2010) 1.75

VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. Pharmacogenomics (2008) 1.65

Role of activating FcγR gene polymorphisms in Kawasaki disease susceptibility and intravenous immunoglobulin response. Circ Cardiovasc Genet (2012) 1.65

Genome scan of glomerular filtration rate and albuminuria: the HyperGEN study. Nephrol Dial Transplant (2006) 1.59

Quantitative-trait loci influencing body-mass index reside on chromosomes 7 and 13: the National Heart, Lung, and Blood Institute Family Heart Study. Am J Hum Genet (2001) 1.59

Relationship of interleukin-6 with regional and global left-ventricular function in asymptomatic individuals without clinical cardiovascular disease: insights from the Multi-Ethnic Study of Atherosclerosis. Eur Heart J (2010) 1.58

Trans-ethnic fine-mapping of lipid loci identifies population-specific signals and allelic heterogeneity that increases the trait variance explained. PLoS Genet (2013) 1.57

Pharmacogenetic association of hypertension candidate genes with fasting glucose in the GenHAT Study. J Hypertens (2010) 1.55

A summary of the effects of antihypertensive medications on measured blood pressure. Am J Hypertens (2005) 1.55

Health-related quality of life and survival in liver transplant candidates. Liver Transpl (2010) 1.55

Trends in the trans-fatty acid composition of the diet in a metropolitan area: the Minnesota Heart Survey. J Am Diet Assoc (2003) 1.54

Aortic valve sclerosis is associated with preclinical cardiovascular disease in hypertensive adults: the Hypertension Genetic Epidemiology Network study. J Hypertens (2005) 1.49

Vemurafenib enhances MHC induction in BRAF(V600E) homozygous melanoma cells. Oncoimmunology (2013) 1.47

Assessment of the interaction of heritability of volume load and left ventricular mass: the HyperGEN offspring study. J Hypertens (2007) 1.46

Family history of premature coronary heart disease and coronary artery calcification: Multi-Ethnic Study of Atherosclerosis (MESA). Circulation (2007) 1.44

Hemodynamic and echocardiographic profiles in African American compared with White offspring of hypertensive parents: the HyperGEN study. Am J Hypertens (2013) 1.43

Linkage of the cholesterol 7alpha-hydroxylase gene and low-density lipoprotein cholesterol conditional on apolipoprotein E association: the National Heart, Lung, and Blood Institute Family Heart Study. Chin Med J (Engl) (2005) 1.42

Lifestyle determinants of high-density lipoprotein cholesterol: the National Heart, Lung, and Blood Institute Family Heart Study. Am Heart J (2004) 1.41

Career panel for pathology residents: going beyond the core curriculum. Am J Clin Pathol (2014) 1.39

Development and evaluation of a real-time PCR assay for detection of Klebsiella pneumoniae carbapenemase genes. J Clin Microbiol (2008) 1.39

Clinical evaluation of an automated nucleic acid isolation system. Clin Chem (2002) 1.39

Epigenome-wide association study of fasting measures of glucose, insulin, and HOMA-IR in the Genetics of Lipid Lowering Drugs and Diet Network study. Diabetes (2013) 1.38

Alcohol consumption and metabolic syndrome: does the type of beverage matter? Obes Res (2004) 1.38

SNPs located at CpG sites modulate genome-epigenome interaction. Epigenetics (2013) 1.37

Genome-wide meta-analysis of observational studies shows common genetic variants associated with macronutrient intake. Am J Clin Nutr (2013) 1.35

Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy. Thromb Haemost (2011) 1.35

A genome-wide association study of inflammatory biomarker changes in response to fenofibrate treatment in the Genetics of Lipid Lowering Drug and Diet Network. Pharmacogenet Genomics (2012) 1.35

Effect of influenza vaccine on markers of inflammation and lipid profile. J Lab Clin Med (2005) 1.31

Association of kidney function and hemoglobin with left ventricular morphology among African Americans: the Atherosclerosis Risk in Communities (ARIC) study. Am J Kidney Dis (2004) 1.30

Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension. JAMA (2008) 1.30

Metabolic syndrome and echocardiographic left ventricular mass in blacks: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation (2005) 1.29

Normal limits in relation to age, body size and gender of two-dimensional echocardiographic aortic root dimensions in persons ≥15 years of age. Am J Cardiol (2012) 1.29

The PLIN4 variant rs8887 modulates obesity related phenotypes in humans through creation of a novel miR-522 seed site. PLoS One (2011) 1.28

Association of left ventricular hypertrophy with metabolic risk factors: the HyperGEN study. J Hypertens (2002) 1.27

An investigation of the effects of lipid-lowering medications: genome-wide linkage analysis of lipids in the HyperGEN study. BMC Genet (2007) 1.27

Accuracy of estimation of large food portions. J Am Diet Assoc (2004) 1.24

CLOCK genetic variation and metabolic syndrome risk: modulation by monounsaturated fatty acids. Am J Clin Nutr (2009) 1.24

Trends in the prevalence, awareness, treatment and control of high low density lipoprotein-cholesterol among United States adults from 1999-2000 through 2009-2010. Am J Cardiol (2013) 1.24

Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factors. Circulation (2008) 1.24

Linkage analysis of a composite factor for the multiple metabolic syndrome: the National Heart, Lung, and Blood Institute Family Heart Study. Diabetes (2003) 1.24

Fruit and vegetable consumption and LDL cholesterol: the National Heart, Lung, and Blood Institute Family Heart Study. Am J Clin Nutr (2004) 1.23

Arterial stiffness is greater in African Americans than in whites: evidence from the Forsyth County, North Carolina, ARIC cohort. Am J Hypertens (2004) 1.22

Renin-angiotensin inhibition in systolic heart failure and chronic kidney disease. Am J Med (2012) 1.22

APOA2, dietary fat, and body mass index: replication of a gene-diet interaction in 3 independent populations. Arch Intern Med (2009) 1.22

A high intake of saturated fatty acids strengthens the association between the fat mass and obesity-associated gene and BMI. J Nutr (2011) 1.20

Epstein-Barr virus-associated smooth muscle tumors are distinctive mesenchymal tumors reflecting multiple infection events: a clinicopathologic and molecular analysis of 29 tumors from 19 patients. Am J Surg Pathol (2006) 1.20

A genome-wide scan of pulmonary function measures in the National Heart, Lung, and Blood Institute Family Heart Study. Am J Respir Crit Care Med (2003) 1.19

A whole-genome scan for stroke or myocardial infarction in family blood pressure program families. Stroke (2008) 1.18

Comparison of ultracentrifugation and nuclear magnetic resonance spectroscopy in the quantification of triglyceride-rich lipoproteins after an oral fat load. Clin Chem (2004) 1.17

Erythrocyte fatty acid composition and the metabolic syndrome: a National Heart, Lung, and Blood Institute GOLDN study. Clin Chem (2007) 1.17

Interleukin1beta genetic polymorphisms interact with polyunsaturated fatty acids to modulate risk of the metabolic syndrome. J Nutr (2007) 1.15

ADIPOQ polymorphisms, monounsaturated fatty acids, and obesity risk: the GOLDN study. Obesity (Silver Spring) (2008) 1.15

Left ventricular concentric geometry is associated with impaired relaxation in hypertension: the HyperGEN study. Eur Heart J (2004) 1.15

Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics. Pharmacogenomics (2008) 1.14

Smoking, inflammatory patterns and postprandial hypertriglyceridemia. Atherosclerosis (2008) 1.14

Optimal threshold value for left ventricular hypertrophy in blacks: the Atherosclerosis Risk in Communities study. Hypertension (2004) 1.13

Echocardiographic left ventricular mass in African-Americans: the Jackson cohort of the Atherosclerosis Risk in Communities Study. Echocardiography (2003) 1.12

A genome-wide affected sibpair linkage analysis of hypertension: the HyperGEN network. Am J Hypertens (2003) 1.12

Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR 677C>T, MTHFR 1298 A>C, and CBSins) and the efficacy of HMG-CoA reductase inhibitors in preventing cardiovascular disease in high-risk patients of hypertension: the GenHAT study. Pharmacogenet Genomics (2008) 1.12

Prevalence and correlates of low medication adherence in apparent treatment-resistant hypertension. J Clin Hypertens (Greenwich) (2012) 1.10

Genetic effect on blood pressure is modulated by age: the Hypertension Genetic Epidemiology Network Study. Hypertension (2008) 1.10

Association of common C-reactive protein (CRP) gene polymorphisms with baseline plasma CRP levels and fenofibrate response: the GOLDN study. Diabetes Care (2008) 1.09

Divided States of America: regional variation in cardiovascular health. J Am Heart Assoc (2012) 1.09

The genetic architecture of fasting plasma triglyceride response to fenofibrate treatment. Eur J Hum Genet (2008) 1.09

A genome-wide association study of carotid atherosclerosis in HIV-infected men. AIDS (2010) 1.08

Association of low-grade albuminuria with adverse cardiac mechanics: findings from the hypertension genetic epidemiology network (HyperGEN) study. Circulation (2013) 1.07